Bortezomib synergizes with pirarubicin to induce growth arrest of T cell lymphoma Hut-78 cells

Ya Jing Yu, Hua Qing Wang, Qian Zheng-zi, Zhang Hui-lai, Ma Yan-ling, F. U. Kai, H. A.O. Xi-shan

Research output: Contribution to journalArticle

Abstract

Objective: To investigate the cytotoxic effect of bortezomib (BTZ) on human cutaneous T-cell lymphoma Hut-78 cell line and the antitumor activity of BTZ combined with pirarubicin (THP) on tumor cells. Methods: The effects of BTZ, THP alone, or BTZ plus THP, on the proliferation of Hut-78 cells were determined by MTT assay. Results: BTZ and THP alone effectively induced growth inhibition of Hut-78 cells in a time-and dose-dependent manner, with an 50 % inhibiting concentration of 8.53 nmol/L and 2515.27 μg/L individually after 48 hours of culture. BTZ plus THP had an impressive antitumor efficacy compared with single agent. The combination index analysis showed significant synergistic effects when treated with BTZ followed by THP and concurrent BTZ plus THP, especially for the former. Conclusion: BTZ alone or combined with THP significantly inhibited the growth of Hut-78 cells in vitro. Our study demonstrated that BTZ plus THP presents a synergistically antitumor effect on T cell lymphoma cells and may be an optimal regimen in clinical trial of T cell lymphoma.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalJournal of Leukemia and Lymphoma
Volume19
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

T-Cell Lymphoma
Growth
Bortezomib
pirarubicin
Cutaneous T-Cell Lymphoma
Clinical Trials
Cell Line

Keywords

  • Cell line, tumor, cell proliferation
  • Depression, chemical
  • Drug antagonism
  • Lymphoma, T-cell

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bortezomib synergizes with pirarubicin to induce growth arrest of T cell lymphoma Hut-78 cells. / Yu, Ya Jing; Wang, Hua Qing; Zheng-zi, Qian; Hui-lai, Zhang; Yan-ling, Ma; Kai, F. U.; Xi-shan, H. A.O.

In: Journal of Leukemia and Lymphoma, Vol. 19, No. 2, 01.02.2010, p. 75-77.

Research output: Contribution to journalArticle

Yu, Ya Jing ; Wang, Hua Qing ; Zheng-zi, Qian ; Hui-lai, Zhang ; Yan-ling, Ma ; Kai, F. U. ; Xi-shan, H. A.O. / Bortezomib synergizes with pirarubicin to induce growth arrest of T cell lymphoma Hut-78 cells. In: Journal of Leukemia and Lymphoma. 2010 ; Vol. 19, No. 2. pp. 75-77.
@article{33a7350e1e4641e7b5f4d20a57d581dc,
title = "Bortezomib synergizes with pirarubicin to induce growth arrest of T cell lymphoma Hut-78 cells",
abstract = "Objective: To investigate the cytotoxic effect of bortezomib (BTZ) on human cutaneous T-cell lymphoma Hut-78 cell line and the antitumor activity of BTZ combined with pirarubicin (THP) on tumor cells. Methods: The effects of BTZ, THP alone, or BTZ plus THP, on the proliferation of Hut-78 cells were determined by MTT assay. Results: BTZ and THP alone effectively induced growth inhibition of Hut-78 cells in a time-and dose-dependent manner, with an 50 {\%} inhibiting concentration of 8.53 nmol/L and 2515.27 μg/L individually after 48 hours of culture. BTZ plus THP had an impressive antitumor efficacy compared with single agent. The combination index analysis showed significant synergistic effects when treated with BTZ followed by THP and concurrent BTZ plus THP, especially for the former. Conclusion: BTZ alone or combined with THP significantly inhibited the growth of Hut-78 cells in vitro. Our study demonstrated that BTZ plus THP presents a synergistically antitumor effect on T cell lymphoma cells and may be an optimal regimen in clinical trial of T cell lymphoma.",
keywords = "Cell line, tumor, cell proliferation, Depression, chemical, Drug antagonism, Lymphoma, T-cell",
author = "Yu, {Ya Jing} and Wang, {Hua Qing} and Qian Zheng-zi and Zhang Hui-lai and Ma Yan-ling and Kai, {F. U.} and Xi-shan, {H. A.O.}",
year = "2010",
month = "2",
day = "1",
doi = "10.3760/cma.j.issn.1009-9921.2010.02.004",
language = "English (US)",
volume = "19",
pages = "75--77",
journal = "Journal of Leukemia and Lymphoma",
issn = "1009-9921",
publisher = "Editorial Board of Journal of Leukemia and Lymphoma",
number = "2",

}

TY - JOUR

T1 - Bortezomib synergizes with pirarubicin to induce growth arrest of T cell lymphoma Hut-78 cells

AU - Yu, Ya Jing

AU - Wang, Hua Qing

AU - Zheng-zi, Qian

AU - Hui-lai, Zhang

AU - Yan-ling, Ma

AU - Kai, F. U.

AU - Xi-shan, H. A.O.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Objective: To investigate the cytotoxic effect of bortezomib (BTZ) on human cutaneous T-cell lymphoma Hut-78 cell line and the antitumor activity of BTZ combined with pirarubicin (THP) on tumor cells. Methods: The effects of BTZ, THP alone, or BTZ plus THP, on the proliferation of Hut-78 cells were determined by MTT assay. Results: BTZ and THP alone effectively induced growth inhibition of Hut-78 cells in a time-and dose-dependent manner, with an 50 % inhibiting concentration of 8.53 nmol/L and 2515.27 μg/L individually after 48 hours of culture. BTZ plus THP had an impressive antitumor efficacy compared with single agent. The combination index analysis showed significant synergistic effects when treated with BTZ followed by THP and concurrent BTZ plus THP, especially for the former. Conclusion: BTZ alone or combined with THP significantly inhibited the growth of Hut-78 cells in vitro. Our study demonstrated that BTZ plus THP presents a synergistically antitumor effect on T cell lymphoma cells and may be an optimal regimen in clinical trial of T cell lymphoma.

AB - Objective: To investigate the cytotoxic effect of bortezomib (BTZ) on human cutaneous T-cell lymphoma Hut-78 cell line and the antitumor activity of BTZ combined with pirarubicin (THP) on tumor cells. Methods: The effects of BTZ, THP alone, or BTZ plus THP, on the proliferation of Hut-78 cells were determined by MTT assay. Results: BTZ and THP alone effectively induced growth inhibition of Hut-78 cells in a time-and dose-dependent manner, with an 50 % inhibiting concentration of 8.53 nmol/L and 2515.27 μg/L individually after 48 hours of culture. BTZ plus THP had an impressive antitumor efficacy compared with single agent. The combination index analysis showed significant synergistic effects when treated with BTZ followed by THP and concurrent BTZ plus THP, especially for the former. Conclusion: BTZ alone or combined with THP significantly inhibited the growth of Hut-78 cells in vitro. Our study demonstrated that BTZ plus THP presents a synergistically antitumor effect on T cell lymphoma cells and may be an optimal regimen in clinical trial of T cell lymphoma.

KW - Cell line, tumor, cell proliferation

KW - Depression, chemical

KW - Drug antagonism

KW - Lymphoma, T-cell

UR - http://www.scopus.com/inward/record.url?scp=77949810739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949810739&partnerID=8YFLogxK

U2 - 10.3760/cma.j.issn.1009-9921.2010.02.004

DO - 10.3760/cma.j.issn.1009-9921.2010.02.004

M3 - Article

AN - SCOPUS:77949810739

VL - 19

SP - 75

EP - 77

JO - Journal of Leukemia and Lymphoma

JF - Journal of Leukemia and Lymphoma

SN - 1009-9921

IS - 2

ER -